OncoMatch/Clinical Trials/NCT07864701
Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers
Official title: A Phase I/II Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity and Efficacy of JMBI-001 Tablets in Participants With MYC-Positive Advanced Solid Tumors or Relapsed/Refractory Non-Hodgkin Lymphoma
Is NCT07864701 recruiting? Yes, currently enrolling (Oct 2026). This Phase 1/2 trial studies JMBI-001 Tablets for advance solid tumors.
Treatment: JMBI-001 Tablets — Evaluate the safety and tolerability of JMBI-001 in adults with MYC-positive advanced cancers.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MYC overexpression (≥10% tumor cell nuclei (solid tumors); ≥40% tumor cell nuclei (NHL))
tumor tissue ... tested by immunohistochemistry and meet the following criteria for MYC positivity: Solid tumors: MYC-positive tumor cell nuclei in at least 10% of tumor cells. Non-Hodgkin lymphoma: MYC-positive tumor cell nuclei in at least 40% of tumor cells.
Demographics
Prior therapy
Must have received: systemic therapy — non-hodgkin lymphoma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07864701 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received systemic therapy.
Does this trial require MYC?
Yes, MYC overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages